Biotechnology Innovation Organization (BIO)
NEWS
Multiple reports suggest an exodus of BIO team members over price control issues. BIO reorganized its leadership structure to provide what was expected to be “long-term stability for the organization.”
The panels discussed key issues such as expanded access programs (EAPs), clinical trial diversity, conditional approval pathways, and patient experience data.
The COVID-19 pandemic is not only an international health crisis, but a burgeoning geopolitical exercise for Russia to win the hearts and minds of a large portion of the world while undermining the West.
Less than a year after taking over the reins, Biotechnology Innovation Organization Chief Executive Officer Michelle McMurry-Heath is reorganizing the organization’s leadership structure.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.
COVID-19-related testimonies will continue in Congress today, with representatives from the Biotechnology Innovation Organization (BIO) expected to address the current pandemic as well as key priorities that will need to be in place in order to effectively respond to the next global viral threat.
Although clinical trials are often performed throughout different parts of the world, often their demographic makeup—the gender, age and race of participants—has a certain kind of uniformity.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.
Fauci, a longtime infectious disease expert, said COVID-19 is the stuff of nightmares in the way it has quickly spread across the globe, infected millions of people and contributed to the deaths of more than 408,000 people.
JOBS
IN THE PRESS